Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12811523 | 0.91 | HSP90AB1 (0.38) | HSP90AB1HSP90AA1DPP4DPP8DPP9 | |
| SCHEMBL1425365 | 0.84 | HTR4 (0.35) | HSP90AB1HSP90AA1DPP4CYP3A4 | |
| SCHEMBL1425638 | 0.82 | HSP90AB1 (0.38) | HSP90AB1HSP90AA1DPP4DPP8CYP3A4 | |
| SCHEMBL1426051 | 0.81 | SUV39H2 (0.35) | HSP90AB1HSP90AA1DPP4 | |
| SCHEMBL4449692 | 0.81 | HSP90AA1 (0.42) | HSP90AB1HSP90AA1CYP3A4 | |
| SCHEMBL13394094 | 0.80 | CYP3A4 (0.45) | DPP4CYP3A4 | |
| SCHEMBL1425921 | 0.80 | DPP4 (0.41) | HSP90AB1HSP90AA1DPP4CYP3A4 | |
| SCHEMBL14135050 | 0.80 | HTT (0.37) | HSP90AB1HSP90AA1DPP4CYP3A4 | |
| SCHEMBL12811920 | 0.80 | HSP90AA1 (0.47) | HSP90AB1HSP90AA1CYP3A4 | |
| SCHEMBL1425538 | 0.80 | HSP90AA1 (0.55) | HSP90AB1HSP90AA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118111-B1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885DPP4 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.